At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China

被引：10

作者：

Shen, Man ^{[1
]}

Yang, Guangzhong ^{[1
]}

Li, Xin ^{[1
]}

Geng, Chuanying ^{[1
]}

Huang, Zhongxia ^{[1
]}

Chen, Wenming ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Chao Yang Hosp, Multiple Myeloma Med Ctr Beijing, Dept Hematol, Beijing, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 12期

关键词：

Multiple myeloma; double hit; cytogenetic abnormality; chromosome; 1q21; bortezomib; prognosis; FISH;

D O I：

10.1080/10428194.2021.1948032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We retrospectively studied the impact of cytogenetic abnormalities in 328 consecutive newly diagnosed multiple myeloma (MM) patients. High-risk cytogenetic abnormalities (HRCAs) included del (17p), amp/gain (1q21), t(4;14), and t(14;16). We defined a standard-risk group by the absence of HRCA, an intermediate-risk group with one HRCA, and a high-risk (HiR) group with at least two HRCAs. The HiR group constituted 14.3% of patients and was associated with a median overall survival (OS) of 28.6 months and progression-free survival (PFS) of 14.0 months. Moreover, the HiR group predicted poor outcomes for OS and PFS in multivariate analyses, and bortezomib prolongation to nine cycles could not bring additional benefit to this entity, suggesting the necessity of more effective therapies for these patients. Furthermore, we confirmed the independent prognostic impact of amp 1q21 in this real-world study.

引用

页码：2992 / 3001

页数：10

共 27 条

[1] Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities [J].

Abdallah, Nadine ;

Greipp, Patricia ;

Kapoor, Prashant ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Baughn, Linda B. ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie ;

Hobbs, Miriam ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem ;

Lust, John ;

Kyle, Robert A. ;

Bergsagel, Leif ;

Ketterling, Rhett ;

Rajkumar, S. Vincent ;

Kumar, Shaji K. .

BLOOD ADVANCES, 2020, 4 (15) :3509-3519

[2]

Baker GL, 2005, CELL CYCLE, V4, P330

[3] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].

Boyd, K. D. ;

Ross, F. M. ;

Chiecchio, L. ;

Dagrada, G. P. ;

Konn, Z. J. ;

Tapper, W. J. ;

Walker, B. A. ;

Wardell, C. P. ;

Gregory, W. M. ;

Szubert, A. J. ;

Bell, S. E. ;

Child, J. A. ;

Jackson, G. H. ;

Davies, F. E. ;

Morgan, G. J. .

LEUKEMIA, 2012, 26 (02) :349-355

[4] 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib [J].

Du, Chenxing ;

Mao, Xuehan ;

Xu, Yan ;

Yan, Yuting ;

Yuan, Chenglu ;

Du, Xin ;

Liu, Jiahui ;

Fan, Huishou ;

Wang, Qi ;

Sui, Weiwei ;

Deng, Shuhui ;

Fu, Mingwei ;

Li, Zengjun ;

Li, Chengwen ;

Zhao, Jiawei ;

Yi, Shuhua ;

Liu, Lanting ;

Hao, Mu ;

Zou, Dehui ;

Zhao, Yaozhong ;

Qiu, Lugui ;

An, Gang .

LEUKEMIA & LYMPHOMA, 2020, 61 (05) :1201-1210

[5] Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China [J].

Gao, Wen ;

Jian, Yuan ;

Du, Juan ;

Li, Xiaozhe ;

Zhou, Huixing ;

Zhang, Zhiyao ;

Yang, Guangzhong ;

Wang, Guorong ;

Tian, Ying ;

Li, Yanchen ;

Wu, Yin ;

Fu, Weijun ;

Li, Juan ;

Chen, Wenming .

CANCER MEDICINE, 2020, 9 (21) :7819-7829

[6] Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement [J].

Gonsalves, Wilson I. ;

Buadi, Francis K. ;

Ailawadhi, Sikander ;

Bergsagel, P. Leif ;

Khan, Asher A. Chanan ;

Dingli, David ;

Dispenzieri, Angela ;

Fonseca, Rafael ;

Hayman, Susan R. ;

Kapoor, Prashant ;

Kourelis, Taxiarchis V. ;

Lacy, Martha Q. ;

Larsen, Jeremy T. ;

Muchtar, Eli ;

Reeder, Craig B. ;

Sher, Taimur ;

Stewart, A. Keith ;

Warsame, Rahma ;

Go, Ronald S. ;

Kyle, Robert A. ;

Leung, Nelson ;

Lin, Yi ;

Lust, John A. ;

Russell, Stephen J. ;

Zeldenrust, Stephen R. ;

Fonder, Amie L. ;

Hwa, Yi L. ;

Hobbs, Miriam A. ;

Mayo, Angela A. ;

Hogan, William J. ;

Rajkumar, S. Vincent ;

Kumar, Shaji K. ;

Gertz, Morie A. ;

Roy, Vivek .

BONE MARROW TRANSPLANTATION, 2019, 54 (03) :353-367

[7] Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data [J].

He, Jingsong ;

He, Donghua ;

Han, Xiaoyan ;

Zheng, Gaofeng ;

Wei, Guoqing ;

Zhao, Yi ;

Yang, Yang ;

Wu, Wenjun ;

Fu, Jiaping ;

Shou, Lihong ;

Kong, Hongwei ;

Huang, He ;

Cai, Zhen .

FRONTIERS IN PHARMACOLOGY, 2020, 11

[8] Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations [J].

Ji, Misuk ;

Jang, Seongsoo ;

Lee, Je-Hwan ;

Seo, Eul-Ju .

ANNALS OF HEMATOLOGY, 2013, 92 (08) :1129-1131

[9] The multiple myelomas - current concepts in cytogenetic classification and therapy [J].

Kumar, Shaji K. ;

Rajkumar, S. Vincent .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (07) :409-421

[10]

Kyle RA, 2003, BRIT J HAEMATOL, V121, P749

← 1 2 3 →